Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00134719
First received: August 10, 2005
Last updated: June 26, 2014
Last verified: June 2014
  Purpose

This study is evaluating the safety and immunogenicity of Hib-MenCY-TT vaccine compared to control groups receiving licensed Hib or MenC conjugate vaccines, each administered at 2, 4, 6, and 12 to 15 months of age. Co-administration with live, attenuated measles, mumps, and rubella combination vaccine; and with live, attenuated varicella vaccine will be assessed with administration of the booster dose. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.


Condition Intervention Phase
Neisseria Meningitidis
Haemophilus Influenzae Type b
Biological: MenHibrix (Hib-MenCY-TT)
Biological: Infanrix® Penta
Biological: Prevenar®
Biological: ActHIB®
Biological: Meningitec®
Biological: M-M-R®II
Biological: Varivax®
Biological: PedvaxHIB®
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Multicentre Primary & Booster Vaccination Study of GSK Biologicals' Hib-MenCY-TT Conjugate Vaccine vs ActHIB® & MenC Conjugate Licensed Vaccine When Given According to the 2-4-6 Month Schedule to Healthy Infants With Booster Dose at 12 to 15 Months

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Subjects With Anti-polyribosyl-ribitol-phosphate (Anti-PRP) Concentration Greater Than or Equal to 1.0 Microgram Per Milliliter (µg/mL) [ Time Frame: One month after the 3-dose primary vaccination course ] [ Designated as safety issue: No ]
    The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB/PedvaxHib groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.

  • Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Baby Rabbit Complement (rSBA-MenC) Titer Greater Than or Equal to 1:128 [ Time Frame: One month after the 3-dose primary vaccination course ] [ Designated as safety issue: No ]
    The analysis was performed on blood samples taken from half of the subjects in the MenHibrix and ActHIB + Meningitec groups only. The other half of the subjects in these study groups donated a blood sample after the second vaccine dose for analysis of the corresponding secondary outcome measure.

  • Number of Subjects Seroconverted for Anti-measles Antibodies [ Time Frame: 42 days after the fourth dose vaccination ] [ Designated as safety issue: No ]
    The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-measles seroconversion is defined as the appearance of antibodies (i.e. concentration greater than or equal to the cut-off value of 150 milli-international units per milliliter (mIU/mL)) in the serum of subjects seronegative (below 150 mIU/mL) before vaccination.

  • Number of Subjects Seroconverted for Anti-mumps Antibodies [ Time Frame: 42 days after the fourth dose vaccination ] [ Designated as safety issue: No ]

    The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-mumps seroconversion is defined as titer greater than or equal to 28 ED50 in subjects seronegative (<28 ED50) before vaccination.

    ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.


  • Number of Subjects With an Anti-rubella Seroresponse [ Time Frame: 42 days after the fourth dose vaccination ] [ Designated as safety issue: No ]
    The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-rubella seroresponse is defined as post-vaccination concentration greater than or equal to 10 IU/mL (ELISA, Enzygnost) in subjects seronegative (concentration below 4 IU/mL) before vaccination.

  • Number of Subjects Seroconverted for Anti-varicella Antibodies [ Time Frame: 42 days after the fourth dose vaccination ] [ Designated as safety issue: No ]
    The analysis was performed on blood samples taken from the subjects in the MenHibrix and ActHIB groups only. Anti-varicella seroconversion is defined as post-vaccination titers greater than or equal to 1:5, in subjects seronegative (titers below 1:5) before vaccination.


Secondary Outcome Measures:
  • Number of Subjects With rSBA-MenC Titer Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.

  • rSBA-MenC Titers [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.

  • Number of Subjects With rSBA-MenY Titer Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were titers 1:8 and 1:128.

  • rSBA-MenY Titers [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analyses for post-Dose 2 and post-Dose 3 data were performed on blood samples taken from the respective half of the subjects at both time points. Titers are given as Geometric Mean Titers.

  • Number of Subjects With Meningococcal Polysaccharide C Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenC) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.

  • hSBA-MenC Titers [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.

  • Number of Subjects With Meningococcal Polysaccharide Y Serum Bactericidal Activity/Assay Using Human Complement (hSBA-MenY) Antibody Titer Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for was performed on the first 30% of the blood samples taken at each time point. The cut-off values assessed were titers 1:4 and 1:8.

  • hSBA-MenY Titers [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for was performed on the first 30% of the blood samples taken at each time point. Titers are given as Geometric Mean Titers.

  • Number of Subjects With Anti-Polysaccharide C (Anti-PSC) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.

  • Anti-PSC Concentrations [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.

  • Number of Subjects With Anti-Polysaccharide Y (Anti-PSY) Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.3 µg/mL and 2 µg/mL.

  • Anti-PSY Concentrations [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.

  • Number of Subjects With Anti-PRP Antibody Concentration Greater Than or Equal to Pre-defined Cut-off Values [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. The cut-off values assessed were 0.15 µg/mL and 1.0 µg/mL.

  • Anti-PRP Concentrations [ Time Frame: After the second vaccine dose (post-dose 2), one month after the 3-dose primary vaccination course (post-dose 3), just prior to (pre-dose 4) and 42 days after the fourth dose (post-dose 4) ] [ Designated as safety issue: No ]
    The analysis for post-Dose 2 and post-Dose 3 data was performed on blood samples taken from the respective half of the subjects at both time points. Concentrations are given as Geometric Mean Concentrations.

  • Number of Subjects With Anti-measles Concentration Greater Than or Equal to 150 mIU/mL [ Time Frame: Just prior to the fourth dose and 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The cut-off value assessed was 150 mIU/mL.

  • Number of Subjects With Anti-mumps Titer Greater Than or Equal to 24 ED50 [ Time Frame: Just prior to the fourth dose and 42 days after the fourth dose ] [ Designated as safety issue: No ]
    ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.

  • Number of Subjects With Anti-rubella Concentration Greater Than or Equal to 4 IU/mL [ Time Frame: Just prior to the fourth dose and 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The cut-off value assessed was 4 IU/mL.

  • Number of Subjects With Anti-varicella Titer Greater Than or Equal to 1:5 [ Time Frame: Just prior to the fourth dose and 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The cut-off value assessed was a titer of 1:5.

  • Number of Subjects With a Fourth Dose Response for hSBA-MenC [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    Fourth dose response for hSBA-MenC is defined as: •For initially seronegative subjects (i.e., subjects with pre fourth dose hSBA antibody titer below 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:16; •For initially seropositive subjects (i.e., subjects with pre fourth dose antibody titer greater than or equal to 1:4), post fourth dose hSBA antibody titer greater than or equal to 1:128.

  • Number of Subjects With a Fourth Dose Response for hSBA-MenY [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    Fourth dose response for hSBA-MenY defined as: •For initially seronegative subjects (i.e., pre fourth dose hSBA antibody titer < 1:4), post fourth dose hSBA antibody titer greater than or equal to (≥) 1:16; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:4 and < 1:64, post fourth dose hSBA antibody titer at least 4-fold higher than the pre fourth dose hSBA antibody titer; •For initially seropositive subjects with pre fourth dose hSBA antibody titer ≥ 1:64, post fourth dose hSBA antibody titer at least 2-fold higher than the pre fourth dose hSBA antibody titer.

  • Number of Subjects With Anti-measles Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The pre-defined cut-off values were 150 mIU/mL and 200 mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.

  • Anti-measles Concentrations in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    Concentrations are presented as Geometric Mean Concentrations expressed as mIU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 150 mIU/mL.

  • Number of Subjects With Anti-rubella Concentration Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The pre-defined cut-off values were 4 IU/mL and 10 IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-measles concentration below 4 IU/mL.

  • Anti-rubella Concentrations in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    Concentrations are presented as Geometric Mean Concentrations expressed as IU/mL. Initially seronegative subjects are defined as subjects with pre-vaccination anti-rubella concentration below 4 IU/mL.

  • Number of Subjects With Anti-mumps Titer Greater Than or Equal to 28 ED50 in Subjects With Anti-mumps Titer Below 28 ED50 Before Vaccination [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    ED50 is defined as the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent.

  • Number of Subjects With Anti-mumps Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The pre-defined cut-off values were 28 ED50 and 51 ED50. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.

  • Anti-mumps Titers in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    Titers are presented as Geometric Mean Titers expressed as ED50, the reciprocal of the sample dilution in the neutralising assay reducing the number of viral plaques by fifty percent. Initially seronegative subjects are defined as subjects with pre-vaccination anti-mumps titer below 24 ED50.

  • Number of Subjects With Anti-varicella Titer Greater Than or Equal to Predefined Cut-off Values in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    The pre-defined cut-off values were 1:5 and 1:40. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.

  • Anti-varicella Titers in Initially Seronegative Subjects [ Time Frame: 42 days after the fourth dose ] [ Designated as safety issue: No ]
    Titers are presented as Geometric Mean Titers. Initially seronegative subjects are defined as subjects with pre-vaccination anti-varicella titer below 1:5.

  • Number of Subjects Reporting Solicited Local and General Symptoms During the Primary Vaccination Phase [ Time Frame: During a 4-day period (Day 0-3) after any vaccine dose in the primary vaccination phase ] [ Designated as safety issue: No ]
    Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.

  • Number of Subjects Reporting Solicited Local and General Symptoms During the Fourth Dose Vaccination Phase [ Time Frame: During a 4-day period (Day 0-3) after the fourth dose vaccination phase ] [ Designated as safety issue: No ]
    Solicited local symptoms assessed include pain, redness and swelling. Solicited general symptoms assessed include drowsiness, fever (rectal temperature greater than or equal to 38 degrees Celcius), irritability and loss of appetite.

  • Number of Subjects Reporting Unsolicited Adverse Events [ Time Frame: During the 31-day (Day 0-30) post-primary and post-fourth dose vaccination period ] [ Designated as safety issue: No ]
    Unsolicited adverse event covers any adverse event reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

  • Number of Subjects Reporting Specific Solicited General AEs Related to Measles, Mumps, Rubella Vaccine and Varicella Vaccine [ Time Frame: During a 43-day (Day 0-42) after the fourth dose ] [ Designated as safety issue: No ]
    Specific solicited general symptoms assessed include fever (temperature greater than or equal to 38 degrees Celcius), meningismus/ febrile convulsion, parotid / salivary gland swelling and rash.

  • Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Primary Vaccination Phase [ Time Frame: From enrolment through the day preceding the fourth dose ] [ Designated as safety issue: No ]
    SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.

  • Number of Subjects Reporting Serious Adverse Events (SAEs), New Onset of Chronic Illnesses (NOCI), Rash, Emergency Room Visits (ER), Physician Office Visits (PO) During the Fourth Dose Vaccination Phase [ Time Frame: From the day of administration of the fourth dose until the end of the extended safety follow-up period (last study contact at 18-21 months of age ] [ Designated as safety issue: No ]
    SAEs: medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. NOCI: e.g. autoimmune disorders, asthma, type I diabetes and allergies. Types of rash: hives, idiopathic thrombocytopenic purpura and petechiae. ER and PO visits assessed were not related to well-child care, vaccination, injury or common acute illnesses such as upper respiratory tract infection, otitis media, pharyngitis and gastroenteritis.


Enrollment: 1104
Study Start Date: April 2005
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MenHibrix Group
Subjects primed in study 102370 with 3 doses of MenHibrix, Infanrix Penta and Prevenar vaccines and receiving a fourth dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
Biological: MenHibrix (Hib-MenCY-TT)
One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
Biological: Infanrix® Penta
One intramuscular dose at 2, 4 and 6 months of age
Biological: Prevenar®
One intramuscular dose at 2, 4 and 6 months of age
Biological: M-M-R®II
One subcutaneous dose at 12-15 months of age
Biological: Varivax®
One subcutaneous dose at 12 to 15 months of age
Active Comparator: ActHIB + Meningitec Group
Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta, Prevenar and Meningitec vaccines and receiving a dose of MenHibrix co-administered with M-M-RII and Varivax vaccines in study 102371.
Biological: MenHibrix (Hib-MenCY-TT)
One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
Biological: Infanrix® Penta
One intramuscular dose at 2, 4 and 6 months of age
Biological: Prevenar®
One intramuscular dose at 2, 4 and 6 months of age
Biological: ActHIB®
One intramuscular dose at 2, 4 and 6 months of age
Biological: Meningitec®
One intramuscular dose at 2, 4 and 6 months of age
Biological: M-M-R®II
One subcutaneous dose at 12-15 months of age
Biological: Varivax®
One subcutaneous dose at 12 to 15 months of age
Active Comparator: ActHIB/PedvaxHIB Group
Subjects primed in study 102370 with 3 doses of ActHIB, Infanrix Penta and Prevenar vaccines and receiving a dose of PedvaxHIB co-administered with M-M-RII and Varivax vaccines in study 102371.
Biological: Infanrix® Penta
One intramuscular dose at 2, 4 and 6 months of age
Biological: Prevenar®
One intramuscular dose at 2, 4 and 6 months of age
Biological: ActHIB®
One intramuscular dose at 2, 4 and 6 months of age
Biological: M-M-R®II
One subcutaneous dose at 12-15 months of age
Biological: Varivax®
One subcutaneous dose at 12 to 15 months of age
Biological: PedvaxHIB®
One intramuscular dose at 12 to 15 months of age

Detailed Description:

The study will be conducted in 2 stages: a 3-dose primary vaccination at 2, 4 and 6 months of age and a booster vaccination at 12 to 15 months of age. All subjects will have 3 blood samples taken. Half of the subjects of each group will have a blood sample taken just prior to the administration of the third dose of the primary vaccination and the other half of the subjects of each group will have a blood sample taken at one month after the third vaccine dose of the primary vaccination phase. In addition, all subjects of all groups will have a blood sample taken before and 42 days after administration of the booster dose.

  Eligibility

Ages Eligible for Study:   6 Weeks to 12 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects for whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination.
  • Written informed consent obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Born after a gestation period between 36 and 42 weeks.

Exclusion Criteria:

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).
  • Previous vaccination against Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliovirus, and/or Streptococcus pneumoniae; more than one previous dose of hepatitis B vaccine. Vaccination with hepatitis B at birth is accepted (although not mandatory). Influenza vaccination is allowed 30 days after administration of the third vaccine dose to 30 days preceding the booster dose.
  • History of Neisseria meningitidis, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, hepatitis B, poliovirus, Streptococcus pneumoniae and/or varicella invasive disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s), including dry natural latex rubber, tetanus toxoid, diphtheria toxoid, neomycin, polymyxin.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
  • Additional specific criteria for the booster part of the study
  • History of or previous vaccination against measles, mumps, rubella or varicella.
  • Previous booster vaccination with Hib or meningococcal serogroup C vaccine since the last visit of the primary phase.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00134719

Locations
Australia, South Australia
GSK Investigational Site
North Adelaide, South Australia, Australia, 5006
Australia, Victoria
GSK Investigational Site
Carlton, Victoria, Australia, 3053
Australia, Western Australia
GSK Investigational Site
Perth, Western Australia, Australia
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Nolan T et al. (2011) Immunogenicity and Safety of an Investigational Combined Haemophilus influenzae Type B-Neisseria meningitidis Serogroups C and Y-Tetanus Toxoid Conjugate Vaccine. Pediatr Infect Dis J. 30(3):190-196.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00134719     History of Changes
Obsolete Identifiers: NCT00787046
Other Study ID Numbers: 102370 (primary study), 102371
Study First Received: August 10, 2005
Results First Received: June 15, 2012
Last Updated: June 26, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Invasive Hib & N. meningitidis diseases

ClinicalTrials.gov processed this record on November 20, 2014